Ask Us Anything in Clinical Research – Improve Study Performance & Quality With Effective Site and Team Training


On March 23rd, we hosted our virtual networking meeting focused on the complexities of imaging based clinical trials. Heather and Christopher along with their guest Malachi Bierstein of ScienceMedia facilitated a wonderful presentation and discussion around the benefits of effective site training and it’s impact on clinical trial performance! Thank you to everyone who participated…

Read More

Ask Us Anything in Clinical Research – The Ins and Outs of Imaging Based Clinical Trials


On February 25th, we hosted our virtual networking meeting focused on the complexities of imaging based clinical trials. Thank you to everyone who participated in this exciting discussion. For those of you who wanted to join but could not, you can watch the recording below, and also register for our upcoming meetings! Register for the…

Read More

Building a Biotech Program: H2i’s10 Point Plan Workshop


Excerpt from the announcement: Take your first steps toward entrepreneurship with Building a Biotech Venture, a new program for regenerative medicine-focused trainees in labs at the University of Toronto (U of T) and its affiliated hospitals, offered in partnership with the Health Innovation Hub, a campus-linked accelerator at the Temerty Faculty of Medicine at U of T. In the H2i 10…

Read More

Ask Us Anything in Clinical Research – Holiday Virtual Networking Meeting


Yesterday, we held our sixth virtual networking meeting in our ongoing series called Ask us Anything In Clinical Research. This was our Holiday meeting where we reflected on the challenges we all faced during 2020, and discuss what the clinical trials will be like in 2021 and beyond. Thank you to everyone who attended including,…

Read More

NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy


Excerpt from the Press Release: PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–NANOBOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo pre-clinical data from two (2) studies at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting. One…

Read More

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure


Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 13, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with Critical…

Read More

SCOPE International US office celebrates 5th Anniversary


Excerpt from the company announcement: “This summer, the US office of SCOPE International celebrated our 5th Anniversary. There are many words that can be used to describe the journey thus far, but ones that stick out include: Engaging, Challenging, Rewarding, Collaborative, and Family. A big thank you to our partners, clients and each of the…

Read More

Everything you need to know about SR&ED


For our Canadian clients! “Learn about the SR&ED Program and how it benefits health science companies. OBIO will have experts from the CRA to explain the eligibility criteria, what expenditures qualify, and how to file a scientific research and experimental development (SR&ED) claim for this year.” To Register Click the Button Below: Register Free!

Read More

Register for our upcoming “Ask Us Anything In Clinical Research – Medical Device and Diagnostic Studies” virtual networking meeting!


We are absolutely delighted with the positive engagement we’ve had from our first four Ask Us Anything in Clinical Research – Virtual Networking Meetings. It’s hard to believe we have had this many so far! Based on this success, we have decided to continue the series into 2021 with our next virtual meeting on November…

Read More

Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics


Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) — A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Management (“RA Capital”) (collectively the “Investor Group”) together with Sarepta Therapeutics, Inc. (“Sarepta”) (NASDAQ: SRPT), a leader in precision genetic medicine for rare…

Read More